Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGIV 10% in Primary Immunodeficiency Disorders
NCT00157079Phase 3Completed
- Sponsor
- Takeda
- Start
- Jun 2002
- Primary completion
- Dec 2003
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of intravenous immunoglobulin G in primary immunodeficiency disease (PID), sponsored by Takeda. Primary endpoint: Acute Serious Bacterial Infections at 18 months. Started Jun 2002; status: completed.
02
Drugs
intravenous immunoglobulin G
03
Conditions
primary immunodeficiency disease (PID)
Beyond the preview
Go deeper on NCT00157079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00157079.